Scientific Sessions

Immunotherapy and biologics have revolutionized the treatment of rheumatologic disorders, offering targeted approaches to modulate the immune system and control chronic inflammation. Unlike conventional therapies, biologics are engineered proteins that specifically inhibit inflammatory cytokines or immune cells responsible for disease progression. They are widely used in conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and systemic lupus erythematosus, significantly reducing joint damage, pain, and disability. Common biologic agents target tumor necrosis factor (TNF), interleukins (IL-1, IL-6), or B-cells, providing precise and effective disease control where traditional medications may fail.

Immunotherapy in rheumatology extends beyond biologics to include novel small molecules, immune checkpoint modulators, and personalized therapy approaches. These interventions are often combined with conventional disease-modifying antirheumatic drugs (DMARDs) to optimize treatment efficacy while minimizing side effects. Advances in biomarker research allow clinicians to predict patient response and tailor therapy, ensuring a more individualized approach to care. Together, immunotherapy and biologics represent a paradigm shift in rheumatology, offering improved disease management, enhanced quality of life, and better long-term outcomes for patients with complex autoimmune and inflammatory conditions.